Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F

Abstract

The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

1 . A neutralising antibody which binds human IL-17A and human IL-17F, comprising a heavy chain and a light chain, wherein a variable domain of the heavy chain comprises a sequence given in SEQ ID NO:1 for CDR-H1, a sequence given in SEQ ID NO:2 for CDR-H2 and a sequence given in SEQ ID NO:3 for CDR-H3, wherein a variable domain of the light chain comprises a sequence given in SEQ ID NO:4, for CDR-L1, a sequence given in SEQ ID NO:5 for CDR-L2 and a sequence given in SEQ ID NO:6 for CDR-L3 or an antigen binding fragment thereof. 
     
     
         2 . A neutralising antibody which binds human IL-17A and human IL-17F, wherein a heavy chain comprises a sequence given in SEQ ID NO:9. 
     
     
         3 . The neutralising antibody according to  claim 2 , additionally comprising a light chain, wherein the light chain comprises a sequence given in SEQ ID NO:7. 
     
     
         4 . The neutralising antibody according to  claim 1 , having the heavy chain comprising the sequence given in SEQ ID NO:9 and the light chain comprising the sequence given in SEQ ID NO:7. 
     
     
         5 . A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising a sequence given in SEQ ID NO:15 and a light chain comprising a sequence given in SEQ ID NO:11. 
     
     
         6 . A neutralising antibody which binds human IL-17A and human IL-17F, wherein the antibody binds to a same epitope on human IL-17A and human IL-17F as a neutralizing antibody which binds human IL-17A and human IL-17F, and has a heavy chain comprising the sequence given in SEQ ID NO:9 and the light chain comprising the sequence given in SEQ ID NO:7. 
     
     
         7 . The neutralising antibody according to  claim 1 , wherein the antibody fragment is a Fab, Fab′, F(ab′) 2 , scFv or an epitope-binding fragment thereof. 
     
     
         8 . The neutralising antibody according to  claim 7 , wherein the antibody or fragment thereof is a CDR-grafted antibody. 
     
     
         9 . The antibody of  claim 1 , wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s). 
     
     
         10 . An isolated DNA molecule encoding the heavy and/or light chain(s) of an antibody of  claim 1 . 
     
     
         11 . A cloning or expression vector comprising the DNA molecule according to  claim 13 . 
     
     
         12 . The vector according to  claim 11 , wherein the vector comprises a sequences given in SEQ ID NO:14 and the sequence given in SEQ ID NO:18. 
     
     
         13 . An isolated host cell comprising one or more cloning or expression vectors according to  claim 11 . 
     
     
         14 . A process for the production of the antibody encoded by the DNA molecule in the vector of the isolated host cell of  claim 13 , comprising culturing the isolated host cell under conditions suitable for expression of the antibody, and isolating the antibody. 
     
     
         15 . A pharmaceutical composition comprising an antibody of  claim 1 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. 
     
     
         16 . The pharmaceutical composition according to  claim 15 , additionally comprising other active ingredients.